1,174,797 Shares in CVS Health Corporation $CVS Bought by 8 Knots Management LLC

8 Knots Management LLC purchased a new stake in CVS Health Corporation (NYSE:CVS) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 1,174,797 shares of the pharmacy operator’s stock, valued at approximately $88,568,000. CVS Health makes up approximately 10.0% of 8 Knots Management LLC’s investment portfolio, making the stock its 3rd largest holding. 8 Knots Management LLC owned about 0.09% of CVS Health as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Norges Bank purchased a new position in CVS Health in the second quarter worth approximately $1,358,698,000. Wellington Management Group LLP increased its position in shares of CVS Health by 391.6% in the 3rd quarter. Wellington Management Group LLP now owns 6,330,717 shares of the pharmacy operator’s stock valued at $477,273,000 after purchasing an additional 5,042,816 shares during the last quarter. Amundi increased its position in shares of CVS Health by 95.3% in the 3rd quarter. Amundi now owns 7,453,980 shares of the pharmacy operator’s stock valued at $572,665,000 after purchasing an additional 3,637,943 shares during the last quarter. Invesco Ltd. raised its holdings in shares of CVS Health by 15.3% in the 2nd quarter. Invesco Ltd. now owns 23,532,479 shares of the pharmacy operator’s stock valued at $1,623,270,000 after purchasing an additional 3,118,626 shares in the last quarter. Finally, Capital Research Global Investors lifted its position in shares of CVS Health by 24.5% during the 3rd quarter. Capital Research Global Investors now owns 11,469,250 shares of the pharmacy operator’s stock worth $864,667,000 after purchasing an additional 2,253,531 shares during the last quarter. Hedge funds and other institutional investors own 80.66% of the company’s stock.

CVS Health News Summary

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Sanford C. Bernstein upgraded CVS to “outperform” with a $94 price target, signaling upward analyst momentum and providing a clear catalyst for investor sentiment. Occidental Petroleum, CVS, Petco: Top Analyst Calls
• Positive Sentiment: CVS announced a new AI-powered health platform, which could boost growth prospects for care management, digital engagement and margin improvement if adoption scales. CVS to launch new AI-powered health platform
• Positive Sentiment: CVS joined an international movement to become menopause accredited, strengthening its clinical services and retail clinic positioning in women’s health — a niche revenue/traffic driver over time. CVS Health joins international movement to become menopause accredited
• Neutral Sentiment: Analysts are revising fair‑value estimates modestly (one update moved fair value ~US$94→US$96), reflecting balanced views: upside from Medicare Advantage exposure but uncertainty on managed‑care earnings and capital allocation. How The CVS Health (CVS) Story Is Shifting With Medicare Advantage And Valuation Debates
• Neutral Sentiment: Competitive dynamics: a North Carolina health plan is triggering a bidding fight for 2028 Aetna/CVS contracts — potential upside if CVS wins, but outcome uncertain. N.C. Health Plan Sparks 2028 Bidding War Over Aetna And CVS Contracts
• Neutral Sentiment: Market reaction since earnings: commentary and data pieces note the stock has moved modestly since last quarter; investors are parsing guidance and EPS trajectory for cues. Why Is CVS Health (CVS) Down 1.7% Since Last Earnings Report?
• Negative Sentiment: Aetna, a CVS subsidiary, agreed to a $117.7M DOJ settlement over alleged inaccurate diagnosis coding in Medicare Advantage — a material legal headline that keeps compliance and MA reimbursement risk on investors’ radar. Aetna’s US$117.7m Settlement Puts CVS Health Compliance In Focus
• Negative Sentiment: Policy risk: CVS warned it may close 100+ Tennessee pharmacies if proposed PBM legislation passes, highlighting state‑level regulatory risk that could reduce retail footprint and revenues in affected markets. CVS threatens to close 100+ Tennessee pharmacies over PBM legislation

Wall Street Analyst Weigh In

Several equities analysts recently commented on CVS shares. UBS Group reissued an “outperform” rating on shares of CVS Health in a report on Wednesday, December 10th. Robert W. Baird lifted their price target on CVS Health from $82.00 to $92.00 and gave the stock an “outperform” rating in a report on Wednesday, December 10th. The Goldman Sachs Group increased their price objective on CVS Health from $95.00 to $97.00 and gave the company a “buy” rating in a report on Thursday, February 12th. Mizuho raised their target price on CVS Health from $88.00 to $95.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 10th. Finally, TD Cowen restated a “buy” rating on shares of CVS Health in a research note on Friday. Twenty research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $95.05.

CVS Health Price Performance

Shares of CVS opened at $76.14 on Friday. The company has a debt-to-equity ratio of 0.80, a current ratio of 0.84 and a quick ratio of 0.63. CVS Health Corporation has a 1-year low of $58.35 and a 1-year high of $85.15. The stock has a market cap of $96.87 billion, a PE ratio of 55.17, a price-to-earnings-growth ratio of 0.79 and a beta of 0.49. The firm has a fifty day moving average price of $78.17 and a 200 day moving average price of $77.79.

CVS Health (NYSE:CVS) last issued its quarterly earnings data on Tuesday, February 10th. The pharmacy operator reported $1.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.00 by $0.09. CVS Health had a return on equity of 11.31% and a net margin of 0.44%.The company had revenue of $105.69 billion for the quarter, compared to analyst estimates of $103.67 billion. During the same quarter last year, the company posted $1.19 earnings per share. The business’s quarterly revenue was up 8.2% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. As a group, sell-side analysts anticipate that CVS Health Corporation will post 5.89 EPS for the current year.

CVS Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, February 2nd. Shareholders of record on Thursday, January 22nd were paid a $0.665 dividend. The ex-dividend date was Thursday, January 22nd. This represents a $2.66 dividend on an annualized basis and a yield of 3.5%. CVS Health’s payout ratio is currently 192.75%.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.